Summary of spleen volume and symptom reduction from baseline to week 24, by dosing arm
| . | Pacritinib . | |||||
|---|---|---|---|---|---|---|
| 100 mg once per d . | 100 mg twice per d . | 200 mg twice per d . | ||||
| n/N . | % . | n/N . | % . | n/N . | % . | |
| SVR rate | ||||||
| Overall | 0/52 | 0 | 1/55 | 1.8 | 5/54 | 9.3 |
| Evaluable | 0/26 | 0 | 1/26 | 3.8 | 5/27 | 18.5 |
| Patients with platelet count <50 × 103/μL | ||||||
| Overall | 0/23 | 0 | 0/24 | 0 | 4/24 | 16.7 |
| Evaluable | 0/9 | 0 | 0/10 | 0 | 4/13 | 30.8 |
| Median percent spleen volume change from baseline (IQR) | −6.7 (–14.5 to 11.3) | −0.1 (–14.2 to 9.2) | −10.1 (–23.8 to 2.5) | |||
| TSS response rate | ||||||
| Overall | 4/52 | 7.7 | 4/55 | 7.3 | 4/54 | 7.4 |
| Evaluable | 4/23 | 17.4 | 4/27 | 14.8 | 4/24 | 16.7 |
| Patients with platelet count <50 × 103/μL | ||||||
| Overall | 2/23 | 8.7 | 0/24 | 0 | 2/24 | 8.3 |
| Evaluable | 2/9 | 22.2 | 0/10 | 0 | 2/13 | 15.4 |
| Median percent TSS change from baseline (IQR) | −3.1 (–30.4 to 29.3) | −16.0 (–43.5 to 0.8) | −27.3 (–39.2 to 1.2) | |||
| . | Pacritinib . | |||||
|---|---|---|---|---|---|---|
| 100 mg once per d . | 100 mg twice per d . | 200 mg twice per d . | ||||
| n/N . | % . | n/N . | % . | n/N . | % . | |
| SVR rate | ||||||
| Overall | 0/52 | 0 | 1/55 | 1.8 | 5/54 | 9.3 |
| Evaluable | 0/26 | 0 | 1/26 | 3.8 | 5/27 | 18.5 |
| Patients with platelet count <50 × 103/μL | ||||||
| Overall | 0/23 | 0 | 0/24 | 0 | 4/24 | 16.7 |
| Evaluable | 0/9 | 0 | 0/10 | 0 | 4/13 | 30.8 |
| Median percent spleen volume change from baseline (IQR) | −6.7 (–14.5 to 11.3) | −0.1 (–14.2 to 9.2) | −10.1 (–23.8 to 2.5) | |||
| TSS response rate | ||||||
| Overall | 4/52 | 7.7 | 4/55 | 7.3 | 4/54 | 7.4 |
| Evaluable | 4/23 | 17.4 | 4/27 | 14.8 | 4/24 | 16.7 |
| Patients with platelet count <50 × 103/μL | ||||||
| Overall | 2/23 | 8.7 | 0/24 | 0 | 2/24 | 8.3 |
| Evaluable | 2/9 | 22.2 | 0/10 | 0 | 2/13 | 15.4 |
| Median percent TSS change from baseline (IQR) | −3.1 (–30.4 to 29.3) | −16.0 (–43.5 to 0.8) | −27.3 (–39.2 to 1.2) | |||
SVR is defined as ≥35% reduction; TSS (7-component version) response is defined as ≥50% reduction. Response rates are provided for the overall population (all treated patients) and for the evaluable population (patients with week 24 data).